Tamoxifen for High Risk and BRCA1/2

Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group.

Narod SA, Brunet JS, Ghadirian P, Robson M, Heimdal K, Neuhausen SL, Stoppa-Lyonnet D, Lerman C, Pasini B, de los Rios P, Weber B, Lynch HCentre for Research on Women's Health, Women's College Hospital, University of Toronto, Ontario, Canada. steven.narod@swchsc.on.ca

BACKGROUND: Women with a mutation in BRCA1 or BRCA2 have a high risk of developing breast cancer and of contralateral cancer after the initial diagnosis of breast cancer. Tamoxifen protects against contralateral breast cancer in the general population, but whether it protects against contralateral breast cancer in BRCA1 or BRCA2 mutation carriers is not known.

METHODS: We compared 209 women with bilateral breast cancer and BRCA1 or BRCA2 mutation (bilateral-disease cases), with 384 women with unilateral disease and BRCA1 or BRCA2 mutation (controls) in a matched case-control study. Age and age at diagnosis of breast cancer (range 24-74 years) were much the same in bilateral-disease cases and controls, and both groups had been followed up for the same time for a second primary breast cancer. History of tamoxifen use for first breast cancer was obtained by interview, or by self-administered questionnaire.

FINDINGS: The multivariate odds ratio for contralateral breast cancer associated with tamoxifen use was 0.50 (95% CI 0.28-0.89). Tamoxifen protected against contralateral breast cancer for carriers of BRCA1 mutations (odds ratio 0.38, 95% CI 0.19-0.74) and for those with BRCA2 mutations (0.63, 0.20-1.50). In women who used tamoxifen for 2-4 years, the risk of contralateral breast cancer was reduced by 75%. A reduction in risk of contralateral cancer was also seen with oophorectomy (0.42, 0.22-0.83) and with chemotherapy (0-40, 0.26-0.60).

INTERPRETATION: Tamoxifen use reduces the risk of contralateral breast cancer in women with pathogenic mutations in the BRCA1 or BRCA2 gene. The protective effect of tamoxifen seems independent of that of oophorectomy. PMID: 11130383, UI: 21010531

Lancet 2000 Dec 2;356(9245):1876-81


Most Women with Family Hist DO NOT Get Bca

Lancet, 10/01

Tamoxifen and BRCA Mutations

JAMA, 11/01

Estimates of Prophylactic Effects of Tamoxifen *BRCA1&2)

British J of Cancer, 2/02

Breast Cancer Prevention-UK Study

The Oncologist, 2/02

Breast Cancer Prevention-Dialogue w/Richard R. Love
Breast Cancer Prevention-Dialogue w/Victor G. Vogel
Breast Gel Version of Tamoxifen

Ivahoe Newswire, 10/02

Tamoxifen/Chemoprevent/BRCA1/2:Docs Recommendations

J Clin Oncol, 12/03


Remember we are NOT Doctors and have NO medical training.

This site is like an Encyclopedia - there are many pages, many links on many topics.

Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.